Management of Myeloproliferative Neoplasms

home / peer-exchange / mpn-management

An Overview of Myeloproliferative Neoplasms

EP. 1: An Overview of Myeloproliferative Neoplasms

MPNs: Differentiating Between ET, PV, and MF

EP. 2: MPNs: Differentiating Between ET, PV, and MF

Suspecting Polycythemia Vera: Challenges in Diagnosis

EP. 3: Suspecting Polycythemia Vera: Challenges in Diagnosis

Polycythemia Vera: Making a Diagnosis

EP. 4: Polycythemia Vera: Making a Diagnosis

Polycythemia Vera: Considerations for Frontline Therapy

EP. 5: Polycythemia Vera: Considerations for Frontline Therapy

Determining Inadequate Control or Intolerance in PV

EP. 6: Determining Inadequate Control or Intolerance in PV

Polycythemia Vera: Controlling HCT and WBC

EP. 7: Polycythemia Vera: Controlling HCT and WBC

Selecting Appropriate Therapy at Progression of PV

EP. 8: Selecting Appropriate Therapy at Progression of PV

Ruxolitinib's Role in Treating Polycythemia Vera

EP. 9: Ruxolitinib's Role in Treating Polycythemia Vera

Optimizing the Use of Ruxolitinib for Polycythemia Vera

EP. 10: Optimizing the Use of Ruxolitinib for Polycythemia Vera

Myelofibrosis: Diagnosis and Risk Stratification

EP. 11: Myelofibrosis: Diagnosis and Risk Stratification

Ruxolitinib's Role in Treating Myelofibrosis

EP. 12: Ruxolitinib's Role in Treating Myelofibrosis

Polycythemia Vera: Novel JAK Inhibitors

EP. 13: Polycythemia Vera: Novel JAK Inhibitors

Treating Anemia With Luspatercept in MDS

EP. 14: Treating Anemia With Luspatercept in MDS

Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

EP. 15: Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia Vera

Unmet Needs and Future Directions in Treating MPNs

EP. 16: Unmet Needs and Future Directions in Treating MPNs

Latest Conference Coverage

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.